Evaxion A/S (EVAX) Earnings Call Transcript
March 6, 2026
Earnings Call Speaker Segments
Thanks, and hello everybody. I appreciate you being here for Evaxion's business update, which comes after we reported our full year 2025 financial results yesterday. I want to apologize that technical issues pushed this call 24 hours past when we had planned it. It's a pleasure to be with you today. I'm Helen Tayton-Martin, and it's an honor to lead this call for the first time in my role as Evaxion's CEO. Let's go to slide one. Alright. During this call, we'll go over what we accomplished in 2025 and mention the milestones we expect in 2026. After that, our Chief Scientific Officer, Birgitte Rono, will take you through the key R&D updates from the year, covering the newest innovations coming out of our AI-Immunology platform. Then our CFO, Thomas Schmidt, will review our 2025 financial results, and following that we'll wrap up with some closing thoughts and open the floor for questions. Right. On to the next slide. Naturally, what we say and present today might include forward-looking statements, and everyone on this call should refer to our filed SEC statements, in particular our most recent 20th annual report for 2020 filed — 2025 filed yesterday. So let's move to the next slide. I'll begin with what we achieved in 2025 and our 2026 milestones. During 2025, we were extremely happy to share tremendous progress across every pillar of the company. To begin with, on the business development side, we were delighted by how our collaboration with MSD and our infectious disease portfolio advanced, with Merck deciding to exercise its option over our EVX-B3 program candidate. Although the target for this program has not been disclosed, we take great pride that this is, to our knowledge, the first in-licensing of an infectious disease vaccine candidate that was identified and validated through an AI discovery platform. While MSD opted not to exercise its option over our EVX-B2 candidate in gonorrhea, we continue to be very excited about the data and the prospects for this program, for which we have kept full rights and have seen significant interest. We were also happy to enter into a collaboration with the Gates Foundation focused on designing a new polio vaccine, and we are likewise seeing significant interest in our platform and pipeline programs more broadly from a number of parties. On the R&D front, we were very pleased to present very positive 2-year Phase II data at ESMO for our EVX-01 program, which involves a personalized neoantigen-directed cancer vaccine in advanced melanoma patients. We also presented preclinical data at ASH on our first cancer vaccine to a shared antigen — sorry, antigen based directed to a conserved endogenous retroviral EVR elements that we have identified in AML patients with our EVX-04 program. Within our infectious disease portfolio, we also succeeded in advancing a new program with candidates identified from our AI-Immunology platform against Group A Streptococcus. Regarding the platform, the team keeps pushing boundaries and leverages it not just to pinpoint the best vaccine candidates, but also to enhance their design biology for product delivery in our new automated module; Birgitte will cover all those accomplishments soon. We also felt honored when the Galien Foundation acknowledged our AI-Immunology platform for AI progress in human health. Then, we were quite happy about the capital coming into the business during the prior year via financing, business development, and drawing on our ATM, which provides Evaxion with a cash runway extending to the second half of 2027. Thomas will elaborate on that afterward; so let's go to the following slide. As a quick note, Evaxion has assembled a wide, novel product-centered pipeline of assets derived from its distinctive AI-Immunology platform, clinically validated within cancer vaccines through our EVX-01 peptide-based vaccine in advanced melanoma, backed by assets and data across DNA and RNA platforms, along with a preclinical pipeline of infectious disease vaccine candidates aimed at difficult targets that stay intractable using conventional methods and face substantial medical need; on to the following slide. That distinctive AI-Immunology capability is something we've also started exploring in the autoimmune space, since a broader array of diseases are driven by autoimmune attack and our platform applies directly to concentrating on immune mechanisms in disease. Autoimmune diseases impact more than 14 million patients each year in the U.S. and involve chronic debilitating conditions where treatments mainly target symptoms instead of the disease's underlying cause. Moving to the following slide; this explains why we think our AI-Immunology platform is well positioned to target underlying disease mechanisms with greater specificity to pinpoint autoimmune disease targets, which can be tackled in various ways. More updates on this will arrive later in the year. So lastly, on the following slide, let's look at our 2026 milestones. During this year, we'll provide updates on our EVX-01 program with extra biomarkers and immunogenicity data, AACR and then the clinical data, 3-year data toward the — later toward the end of the year. Well, we'll discuss more about the autoimmune uses of our AI-Immunology platform and present data on our new EVX-B4 candidate in Group B — Group A Streptococcus during the second half of the year. And lastly, get ready to file a regulatory application for our next EVX-04 candidate vaccine candidate for the shared ERV antigens in AML by the close of the year. And all along, we stay dedicated to generating value from both our platform and our pipeline assets through partnership for our shareholders and patients. I'll now pass things to Birgitte for more on our R&D achievements.
Helen, thank you. For us, 2025 marked a pivotal year, one in which our R&D pipeline advanced considerably, and our AI platform did as well. Beyond that, as Helen noted, we entered an in-licensing arrangement with MSD covering the EVX-B3 program. Throughout 2025, then, our focus was on strengthening how well our platforms predict, moving our lead R&D assets closer to maturity, and preparing the ground for future partnerships. Given all of that, what we accomplished in 2025 leaves us well positioned for the data-heavy milestones in 2026 that Helen just described. With that said, I'll begin by walking through each of the main programs and our platform work. Let's go to the next slide, please. Our tailored peptide cancer vaccine for advanced melanoma, EVX-01, continues to deliver robust clinical results. In October, during an oral presentation at ESMO, we shared 2-year Phase II findings that demonstrated strong outcomes, including a 75% objective response rate and a 25% complete response rate. What stands out is that at this 2-year point, 92% of those who responded remained in response. On the biomarker side, we saw an exceptionally high immunogenicity hit rate: 81% of all individual new antigens given to patients triggered a specific T-cell response. That remarkable hit rate surpasses what similar programs from other groups have achieved, and it underscores just how accurate our AI-Immunology platform is when it comes to pinpointing the right vaccine targets. Helen already touched on this, but there are two important milestones we're expecting for this program. The first is additional biomarker and immunogenicity data, which should come in the first half of '26. We also plan to share 3-year data from a subset of patients who are currently enrolled in the expansion portion of the Phase II study, and that readout is slated for the second half of '26. A key point here: our goal is to conduct future trials through partnerships so that we can achieve the broadest possible impact for patients. Now, turning to the next slide and EVX-04 — our off-the-shelf therapeutic vaccine for acute myeloid leukemia, or AML — we've produced strong preclinical evidence that supports moving forward with its development. For this program, we're going after an entirely new category of tumor antigens — what are called endogenous retroviruses, or ERVs. These are expressed selectively and at high levels in AML blasts, which makes them appealing as therapeutic targets. Using AI-Immunology, we found millions of short ERV fragments from sequencing data taken from patient tumors, and from there we designed the EVX-04 vaccines, which contain 16 optimal ERV antigen fragments. Those were chosen for their cross-patient relevance as well as their immunological potential. The key data cover in vitro vaccination studies. These show that each of the 16 ERV fragments in the vaccine triggered a strong, specific immune response. They also show that EVX-04 stops tumor growth across multiple mouse tumor models and generates robust T-cell responses. To reiterate, what we've found underscores how capable our platform truly is. And in this case, we've broadened its use to identify distinctive tumor antigens that conventional discovery approaches simply cannot reach. Let's move to the following slide. With EVX-04 moving closer to being ready for the clinic, several important steps are now behind us — among them choosing the antigen and developing the lead. Preclinical work on efficacy has been done, and at present we're conducting extra translational assays that rely on human cells. Our CMC work and GMP manufacturing continue on the timeline we set. For this program, the next major milestone is submitting the clinical trial application in the second half of '26, which would open the door to launching first-in-human testing. This example demonstrates the way AI-Immunology accelerates the vaccine development process, taking it from the earliest idea through to clinical testing. Please advance to the slide that follows. Turning now to our primary programs for infectious diseases: having retained all global rights to EVX-B2 near the close of last year, we currently exercise full authority over the advancement of this highly distinctive vaccine prospect aimed at Neisseria gonorrhoeae. Our collection of preclinical evidence is both strong and comprehensive, demonstrating meaningful protection within a mouse infection model. We have observed wide-ranging effectiveness against 50 isolates of clinical relevance, which indicates coverage spanning varied strains, along with the triggering of notable tumor and cellular responses in mice. Additionally, we have demonstrated a well-documented mechanism of action that is supported by powerful antibody-dependent complement-mediated killing. All things considered, EVX-B2 stands out among preclinical gonorrhea vaccine prospects as exceptionally advanced and distinctive within infectious disease, tackling a significant gap in care since no vaccine has won approval to date. Because our findings are so compelling, we recognize a definite opportunity to work with prospective collaborators in advancing this program into clinical stages. Please move on to the following slide. EVX-B1 represents yet another key vaccine initiative of ours within infectious disease. With this initiative, we're developing a vaccine that goes after multiple targets to fight cytomegalovirus, or CMV. Instead of relying on just one glycoprotein or a small group of them, this effort combines those familiar glycoproteins with newly discovered antigens, allowing it to attack the virus from several complementary directions. The goal behind this broad, multi-component approach is to increase how well the vaccine works while also reducing the chance that the virus finds a way to escape. We've used AI-Immunology to fine-tune the antigens on the known glycoproteins and also to uncover genuinely new antigens. To start, we strengthened the well-established CMV antigens that are critical for neutralizing the virus; within that work, we modified the glycoprotein B antigen by securing it in a prefusion state. This AI-Immunology designed construct has shown a superior neutralization capacity compared to the native protein. Second, we're identifying and validating entirely novel antigens, and several of these have already shown the ability to inhibit viral entry, and we're characterizing them at the moment. With this strong preclinical data supporting it, EVX-B1 represents a highly promising program for continued development and for future partnership discussions. Next slide, please. Now shifting to the recent development of our AI-Immunology platform. Our AI-Immunology platform keeps expanding its capability. The platform integrates multiomic data sets to generate ranked antigen lists within 24 hours; in October last year, we launched an automated vaccine design module enabling sequence and structural optimization directly from these short-listed antigens. This end-to-end automation significantly reduced cost, development time and also risk. Moving to the following slide, if we could. To be more precise, our automated module improves how soluble antigen constructs get designed, which allows for greater expression, superior formulation, and better manufacturability. This capability guides the design of those constructs and additionally solubilizes antigens through inverse folding, yielding an antigen construct that is more dependable than the wild-type variant. What we get from this is a design cycle that is quicker and more economical, and it is completely woven into our workflow for antigen discovery and vaccine optimization. This, then, reinforces the base for every one of our programs spanning oncology and infectious diseases. To wrap up, we've observed robust advancement throughout our platform and our R&D pipeline, and the momentum is heartening to us; we anticipate bringing you further updates as we move forward through 2026. Having said that, I'll pass things over to Thomas, who is going to take us through the financial results.
Yes. Thank you, Birgitte, and let me add my own warm welcome to everyone joining today's call. I'll take you through the 2025 financial results now, so let's move to the next page. Over the course of 2025, we've done really well at extending how far our cash will take us and at bolstering the equity side of things. That came about across the year via a public offering plus the ATM we used in January, then the MSD exercise fee, and the ATM utilized in September. On top of that, investor warrants from our January offering were exercised during October and November, and everything together amounts to USD 32 million of cash coming in. Also, as this slide shows, the EIB debt-to-equity conversion we completed in July totaled USD 4.1 million; we've definitely cut our future cash going out, which of course stretches and enlarges how long our cash runway lasts. And lastly, filing our prospectus supplement for the ATM in December has given us added flexibility and more options as we keep growing our pipeline and platform. So this truly, truly underscores how strongly we executed all year. Moving to the next slide, this leads into the 2025 highlights, where we genuinely hit every target we'd set and are moving toward our goal of turning into a sustainable, self-funding business. Revenue and costs both got better, while we keep putting money into our platform and our pipeline programs. As I said on the prior slide, the MSD deal activities and execution, the EIB debt conversion, and our ATM and capital market activities haven't just bettered our cash position and runway — they've also considerably reinforced our equity. With a better cash runway and equity, we've built more stability and definitely lowered uncertainty too. So I'd say that's truly, truly another highlight for '25. And once more, with the F3 and ATM update, we've swept away the baby-shelf constraints and gained much better flexibility and options supporting our long-term strategic initiatives and the long-term plans we have. The next slide covers our profit and loss statement. As I just said, revenue got better, and we've also made gains on our operational costs. We've actually managed to bring down our operational spend while still delivering the quality we'd want from a pipeline and platform standpoint. Revenue definitely comes from our MSD option exercises, but it's also worth noting we received a grant from the Gates Foundation that came in during 2025 as well — apologies. Our net financial position stands at $0.6 million. What's behind that? A premium we got from converting debt to equity with EIB. Working against that is a remeasurement of a derivative liability, since certain warrants — specifically the ones from our public offering in January — were priced in a different exchange environment, meaning USD against the DKK we report in. For the full year, net loss came to $7.7 million, which is definitely an improvement over the prior year. And like I mentioned earlier, it's also a solid move toward getting to a point where we fund ourselves and turn a profit. Moving to the next slide, covering balance sheet items. We closed out the year holding USD 23 million in cash, and our runway now stretches into the second half of 2027 — that's clearly a meaningful step up from last year as well. Naturally, that money will go toward operating costs and investments in our platform and pipeline. At present, we have total outstanding ADS of $8.3 million, assuming every share has been converted into ADSs. On top of that, by exercising investor warrants, we've brought down the outstanding warrants in ADS terms by $1 million, which means 2.8 million warrants remain outstanding. So that's another area of improvement, and it's genuinely moving things the right way. To sum up, from a financial standpoint, throughout 2025 we built a much stronger base, one that truly positions us well to keep executing our strategy and business through '26 and beyond. With that, I'll turn things back to Helen for a few closing thoughts. Net financial position of $4.6 million.
Thank you, Thomas. Turning now to our final slide. To sum things up, Evaxion experienced a period of robust operational progress during 2025, and over that stretch we hit a number of important milestones. On the whole, we made the business substantially stronger, which validated our approach through our AI-Immunology platform, while also delivering on data and partnerships; that in turn put us in a position to improve our financial standing and cement our role as a frontrunner in AI-driven drug discovery, design and early development. Given that multiple possible partnership conversations are currently underway, the financial milestones we reached in 2025 mean we are funded into the second half of 2027. As a result, we're well placed to advance through 2026. On that note, I'll turn things back to the operator for questions.
Perhaps to kick things off at a high level, Helen — by now you've occupied the role for a handful of months. I'm simply wondering whether you might offer some broad observations regarding what you've put in place or intend to put in place — any strategic shifts? Plus any larger-picture points along those lines that might give us context around your time in the position?
Absolutely. Thank you. Appreciate the question. Right, I came on board at the close of November in the prior year, so these past 3 months have passed incredibly quickly. Even so, I've formed a clear impression already, drawing on my earlier position on the Evaxion Board. Regarding larger-picture shifts. My view is that Evaxion's fundamentals have stayed remarkably solid. As a matter of fact, I believe they've only grown more robust across 2025. Thus, having an AI platform assembled across numerous years, through many rounds of iteration, anchored in data and with lab testing against that data, and finally in the clinic, has genuinely reinforced the central proposition; so I stay genuinely enthusiastic regarding what this platform can achieve in oncology as well as in infectious disease. Also, I believe we're witnessing considerably greater momentum regarding what's possible with the platform at this point via outside engagement; so the essential strengths and the heart of what Evaxion brings to the table are now even more robust than perhaps they were previously. And I believe in an era dominated by AI, actually reaching products, actually generating candidates capable of producing vaccines that trigger a biological response plus a clinical response, matters and is increasingly viewed as mattering, definitely in our partnering discussions, and so on. So that, in my view, sits at the core. That's a clear observation I held prior to joining the company and one certainly reinforced by everything I've noticed since being inside it, and I'm even more struck by the caliber of the team now in place who can execute on this. Regarding the broader strategy, what Evaxion has excelled at is that initial discovery work, that initial validation, that deep scientific and informatic expertise woven throughout, and we can definitely advance things into early clinical development, late preclinical, early clinical; and what we're currently undergoing, I'd say, is a process of truly refining where we perceive the greatest near-term value, both regarding our oncology assets and within the infectious disease space. My sense is we aren't positioned to carry too much further into the clinic; so we've exercised considerable caution on that front, yet we definitely perceive strength and are drawing interest from outside parties concerning the assets we already hold. And indeed, the platform's capability. So there's no basic strategic overhaul, though I'd describe it as a honing and a heightening of emphasis on the assets destined to deliver the greatest value. I hope that proves useful.
Yeah, that's excellent. And building right off what you just said regarding moving products into the clinic — during Birgitte's presentation, you noted that with EVX-04, you'd be aiming to file regulatory documents. Given that ERVs are somewhat novel and somewhat distinct, do you feel that product has to be advanced into Phase I in order to draw partner interest?
That's a really good question, I think. We're definitely getting ready to move it into the clinic, and we feel we're able to do so in order to obtain some early proof of concept. There's considerable interest surrounding the platform — that specific group of candidate antigens in the vaccine. I believe we're conducting additional validation work, which I think will keep making it stronger; so briefly, the answer isn't necessarily yes, but obviously, the more essential validating data we're able to add to the package, the more compelling the value proposition becomes for an external partner, and that's clearly what we're focused on — preserving the — accumulating value for as long as possible to reinforce our position. And I think we have a lot of confidence in what we're capable of achieving with it preclinically and possibly clinically.
Congratulations on the tremendous strides you've achieved. To kick things off, I was hoping you might share a few thoughts regarding the partnership discussions around EVX-01. Specifically, has anything come through in feedback from potential partners that you personally believe we ought to keep an eye on as the next data readouts approach — be it the 3-year results or the biomarker immunogenicity? Is there any one element you'd flag as especially critical when it comes to advancing those partnering conversations?
That's a great question. Obviously, the field of cancer vaccines has a somewhat uneven history — going way back — though I'd say there's been more of a revival, particularly during the checkpoint era. Our data, I believe, is genuinely connecting with organizations focused on cancer vaccines, and they grasp the subtleties involved in securing, I'd say, potent cancer — potent personalized cancer antigens, not merely for immune recognition but for clinical benefit as well. So the — administering this therapy is complex, yet it may also be an effective treatment. And I'd say what tends to attract interest from the — not only the response rate we've observed across 2 years, at 1 year and then 2 years at ESMO, but likewise the antigen recognition, those figures Birgitte referenced, and I'll invite her to weigh in on this too. So I think the — with that updated clinical data package in hand, we're positioned strongly. The translational data, I believe, will prove compelling. It keeps demonstrating why and how the immune response unfolds alongside the clinical response. That, I'd argue, sets us apart, and also within the population — the advanced population, as opposed to the adjuvant melanoma population. And obviously, I think we're likewise witnessing interest in this overall strategy across other cancers with high mutational burden as well; so past melanoma, those are the distinguishing factors, considering where else this might apply, while recognizing the varying biological parameters, the translational insights we're observing that differ somewhat from how competitors have described similar approaches; so there's considerable interest. I think the number — frankly, quite a few companies remain hesitant, yet they're watching keenly and are highly intrigued by the shared approach — the shared antigen approach that our EVX-04 program provides. Birgitte, would you like to offer any additional thoughts?
It's clear that potential partners, along with people in academia, are showing considerable curiosity about how well our AI-Immunology platform can pinpoint the right targets. With that 81% hit rate — the term we use — I'd say it's quite striking. Naturally, we've examined other comparable programs, and the majority of those report hit rates far under 60%, which tells us the antigens they put into their vaccines can't all trigger a specific T cell response. That really speaks to how precise our platform is. So that's one essential piece; the other thing I want to mention is that EVX-01, in our view, isn't only a treatment for advanced melanoma — we think this same idea could prove highly valuable in additional indications marked by a high mutational burden, which means there are multiple antigens available to pick from. That covers a lot of the cancer indications with high prevalence. Non-small cell lung cancer could be one, and certain colorectal cancers as well.
Thank you. I value that extra detail. Then, moving to my next question, I'd like to know whether you might share a little more insight into the way the AI-Immunology platform is being used for autoimmune disease. You called this out as a newly identified area of interest. Also, would you anticipate a stronger emphasis on allergies? Or instead, would the emphasis land more on the big, major autoimmune and inflammatory conditions? Whatever further detail you can offer on this would be useful.
Sure. The first point I'd make, I think, is that when it comes to ranking the indications, we're still at an early stage, though we have definitely carried out some effort in that direction, guided by certain parameters, and — Birgitte, if you'd be willing to weigh in on this, at a high level regarding what shapes where our attention goes, that would be great.
Right. So we've carried out extensive work looking at the autoimmune conditions that occur most often, and a clear match for our platform does show up. That said, we obviously still have to keep refining it and create a handful of extra smaller units so that the immunology can be applied; even so, plenty of what we already have can go straight into this space. Naturally, we'll tell you more once we've finished evaluating which key indications we plan to go after, and once we've put a bit more effort into tuning AI-Immunology so that it suits these conditions. Still, it's worth keeping in mind that many of these smaller units — we refer to them as building blocks — can be used directly for conditions of this kind. And that applies not just to autoimmune diseases, but to other conditions as well in which a strong immunological element is present. So yes, some construction is needed, yet most of it already sits within AI-Immunology.
Thank you. This is RK calling in from H.C. Wainwright. To kick things off, Helen, I've got a quick one for you. At Adaptimmune, you were essentially the person who shaped billion-dollar-plus partnerships — in particular that big transaction signed with GSK. On top of that, you bring a wealth of dealmaking experience. Now, Evaxion is a technically very robust outfit, yet turning that strength into significant deals has always proven hard for them. Granted, Merck is a fairly formidable collaborator. Drawing on what you've been through, and the way you've pulled off that translation, what kinds of conversations might you be having right now? Particularly when you sit down with big pharma players, how do you persuade them that what an AI tool predicts holds up just as well as a wet-lab assay, and get them interested in examining the products coming out of Evaxion?
RK, I appreciate the question. There are, I'd say, several angles to addressing it, insofar as addressing it is even feasible right now. For one thing, much of this comes down to when you act. It comes down to evidence proving this is not merely some kind of AI platform. And honestly, the fact that we can validate and iterate candidates across the span of target discovery, candidate development, and candidate validation is genuinely innovative and not something you typically find available. As for my mention of timing — clearly a great many big pharma companies, most or perhaps every one of them, will be running internal AI platforms in some shape or form. Yet few, in my view, possess the kind of integrated, long — longitudinal depth of know-how that Evaxion brings. So the real task is sharpening what we offer by validating the candidates in hand, plus staying in conversation with the right individuals; and you brought up my history, which spanned a lengthy period — 17 years at my prior organization — cultivating relationships, forging connections, grasping and heeding strategy, watching the broader landscape. Every one of those things plays a major role in how deals come together; and in the end, it hinges on relationships and credibility, and genuinely having something that matches what's needed. What I can tell you today is that we are working — reshaping some of those approaches and themes regarding how we go after potential partnering engagement. I should note the Evaxion team is already recognized by a fair number of these organizations, and we're growing and broadening that visibility. That, I believe, is essential for succeeding in future partnering talks. So it amounts to embodying what you claim to be while standing before the right audience.
Great. And when it comes to the partnership with Merck, particularly on EVX-B2, they chose to prolong their assessment of the molecule instead of picking up the option right now. Is that because they want to run more experiments or functional assays? Or is it that they're asking for further new work in order to reach a conclusion?
Pardon me, do you mean the extension they took last year, prior to that decision?
Yes, yes.
Look, the way those interactions combine — honestly, we're not in a position to say much about that. What I can tell you is that R&D efforts sometimes, when they move back and forth and get shared across companies, don't go according to plan. When that happens, you occasionally have to revisit things. In the end, though, there are schedules attached to these things, and those have to be seen through. So I'd say there are grounds for their decision not to proceed — their rationale, clearly, has many dimensions. What I can tell you is that our enthusiasm for the data hasn't faded at all. In fact, during that whole stretch we kept generating more data on this program in-house; so our confidence in the data package is extremely high and very strong. But the question of how and why Merck chose to carry out that work? Or — that's beyond what we're able to say anything further about.
All right. Regarding EVX-01's durability, Birgitte — you've presented that 92% of those who responded are still showing sustained benefit at 24 months. Now, as we look ahead toward durability at 3 years, which markers of exhaustion will you be monitoring so we can gauge how solid that durability really is?
Yes. Thanks for asking that, RK. It's accurate that 92% of the responders were still in response once we passed the 2-year point. And I believe what you were getting at concerns T-cell exhaustion — correct, we perform extensive T-cell profiling, examining activation markers, exhaustion markers, and additionally various T-cell phenotypes, which includes CD4, CD8, and we also check whether regulatory T-cells are emerging. Thus far, we've shown the T-cell profile to be quite favorable — leaning toward activation or effector-type cells, with not too many carrying exhaustion markers. We also observe what appears to be a dominance of CD4 T-cells, while a subset of patients over time also mount a CD8 T-cell response. So we have — throughout this extension phase of the study, we've been gathering extra blood samples, which our lab is presently analyzing. So there's more to come on that front, but it's really exciting. And given that EVX-01 is administered as a monotherapy during this extension phase, we're also quite eager to learn what EVX-01 is capable of on its own, absent the background of the checkpoint inhibitors.
All right. I've got one final item to ask about. This concerns the EVX-04...
Regarding the program in autoimmune disease, could you share additional specifics about the approach you take to validate candidates at an early stage?
I appreciate that question. What I'd say is that things are at an early point, and additional specifics are likely not something we can offer. That said, Birgitte, would you like to say something about the way we think about this.
Right, so initially we need to lock in a target indication. Landscaping has been completed, and we've run dry analysis examining the 10 most common ultimate diseases. At this point we're whittling that list down to identify which one might be the most — from where we sit — compelling, where AI-Immunology fits really well. That effort continues; it's nearly finished. The following phase involves concentrating on creating the extra, smaller units we'll require within AI-Immunology so we can produce treatments for those diseases. At the same time, we're getting mouse models established in our laboratory, making sure we're able to test the candidates AI-Immunology designs. That's where the plan stands right now — a fairly standard approach for analyzing or testing what AI-Immunology designs.
I appreciate all of you joining today's call. 2025 has been a really strong year for reshaping the business, with Evaxion hitting a number of milestones, and that leaves us financially stronger than we've been in quite a while. Our hope is to keep moving the company ahead, reach our milestones for 2026, and keep building the value generated by the platform and the assets. So thanks for your questions and for being engaged, and we're looking forward to updating you again next time. Thank you. Bye-bye.
Thanks. That wraps up the conference call for today. We appreciate everyone taking part. You're free to disconnect at this point.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Evaxion A/S transcript - plus 132,000+ transcripts from 7,000+ companies, speaker segments and full-text search - through the EarningsAPI REST API or hosted MCP server.
Get an API key View API docs →For developers and AI pipelines
Programmatic access to Evaxion A/S earnings transcripts and 132,000+ others is available through the
EarningsAPI REST API and the hosted MCP server.
Quarterly plans from $162 - full transcripts, speaker segments, full-text search,
and the /api/v1/transcripts/recent polling endpoint for ETL pipelines.